Results 11 to 20 of about 30,645 (194)

TUBB1 promoter methylation is a promising biomarker for predicting HBeAg seroconversion in chronic hepatitis B [PDF]

open access: yesMicrobiology Spectrum
The identification of predictive indices for hepatitis B e antigen seroconversion (HBeAg SC) in patients with chronic hepatitis B (CHB) remains a challenge.
Tong Zhao   +7 more
doaj   +4 more sources

Caucasian Ethnicity, but Not Treatment Cessation Is Associated with HBsAg Loss Following Nucleos(t)ide Analogue-Induced HBeAg Seroconversion [PDF]

open access: yesViruses, 2019
It is well appreciated that ethnicity influences the natural history and immune responses during a chronic hepatitis B infection. In this study, we explore the effect of ethnicity and treatment cessation on Hepatitis B surface Antigen (HBsAg ...
Stijn Van Hees   +12 more
doaj   +4 more sources

Seroconversion of hepatitis B envelope antigen (HBeAg) by entecavir in a child with chronic hepatitis B

open access: yesThe Saudi Journal of Gastroenterology, 2012
Hepatitis B virus (HBV) infection is a worldwide health problem. Consensus guidelines for the treatment of chronic HBV in children have not been established, and indications for antiviral therapy in adults with chronic HBV infection may not be applicable
Mohammed Y Hasosah   +4 more
doaj   +4 more sources

Manifestations of perihepatic lymph nodes in acute flare of chronic hepatitis B: association with HBeAg status and with HBeAg seroconversion. [PDF]

open access: yesPLoS ONE, 2015
UNLABELLED:It has been observed that enlargement of perihepatic lymph nodes may be seen in patients with chronic hepatitis B, particularly during acute flares of CHB.
Yen-Ling Ko   +9 more
doaj   +5 more sources

HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis.

open access: yesPLoS ONE, 2017
BackgroundHBeAg seroconversion is an important intermediate outcome in HBeAg-positive chronic hepatitis B (CHB) patients. This study aimed to compare the effect of nucleos(t)ide analogs (NAs) on HBeAg seroconversion in treating CHB with lamivudine ...
Tongjing Xing   +3 more
doaj   +2 more sources

359 INCREASE RISK OF HBeAg-NEGATIVE CHRONIC HEPATITIS B WITH OLDER AGE AT HBeAg SEROCONVERSION

open access: yesJournal of Hepatology, 2009
Background: Recent evidence suggests that delayed HBeAg seroconversion is associated with poorer outcome. We aim to determine the incidence of HBeAg-negative chronic hepatitis B (CHB) according to the age at which HBeAg seroconversion occurs. Methods:
J. Fung   +4 more
openaire   +2 more sources

HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b

open access: yesChinese Medical Journal, 2016
Background: We aimed to evaluate the usefulness of serum hepatitis B virus core-related antigens (HBcrAg) for predicting hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients treated with conventional interferon (IFN)
Hui Ma   +4 more
doaj   +2 more sources

Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs

open access: yesInfection and Drug Resistance, 2018
 Shaohang Cai,* Zhandong Li,* Tao Yu, Muye Xia, Jie Peng Department of Infectious Diseases and Hepatology Unit, NanFang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China *These authors contributed equally to this ...
Cai S, Li Z, Yu T, Xia M, Peng J
doaj   +1 more source

HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg‐positive patients treated with nucleos(t)ide analogues

open access: yesJournal of Viral Hepatitis, 2018
SummaryHBeAg seroconversion marks an important spontaneous change and treatment end‐point for HBeAg‐positive patients and is a pre‐requisite for HBsAg loss or functional cure. In this retrospective analysis, we aimed to identify predictors of seroconversion using serum quantitative HBsAg and HBcrAg, in HBeAg‐positive patients treated with nucleos(t)ide
B. Wang   +5 more
openaire   +4 more sources

Seroconversion of HBsAg in HBeAg positive and HBeAg negative patients with chronic HBV treated with entecavir: a case series.

open access: yesEuropean review for medical and pharmacological sciences, 2010
We report a case series of three HBeAg positive and five HBeAg negative patients (7 males, mean age 50.6 +/- 14.6 years) with chronic HBV infection experiencing seroconversion after treatment with entecavir (0.5 mg/day or 1 mg/day), initiated in 2007. Overall, the mean time to HBsAg clearance was 9.4 +/- 4.5 months.
G. D'Ettorre   +8 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy